Esperion Therapeutics (ESPR) EBT Margin (2019 - 2026)
Esperion Therapeutics (ESPR) reported EBT Margin of 32.93% for Q1 2026, up 3096.0% on a YoY basis from 1.03% in Q1 2025, and down 188.62% quarter-over-quarter from 37.16% in Q4 2025.
Esperion Therapeutics (ESPR) EBT Margin (2019 - 2026) Analysis & Trends
Esperion Therapeutics has reported EBT Margin for 8 years, with the latest figure at 32.93% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 3096.0% year-over-year to 32.93%; the trailing twelve-month figure through Mar 2026 stood at 2.2% (up 4128.0% YoY), and the FY2025 full-year result was 5.17%, up 1040.0% from the prior year.
- EBT Margin for Q1 2026 stood at 32.93%, down from 37.16% in the prior quarter.
- The five-year high for EBT Margin was 42.29% in Q1 2024, with the low at 353.71% in Q2 2022.
- Historically, EBT Margin has averaged 129.56% across 5 years, with a median of 63.89% in 2025.
- The largest YoY upside for EBT Margin was 83711 bps in 2022 against a maximum downside of 24628 bps in 2022.
- Esperion Therapeutics' EBT Margin stood at 302.06% in 2022, then jumped by 41 bps to 178.06% in 2023, then jumped by 76 bps to 42.07% in 2024, then jumped by 188 bps to 37.16% in 2025, then sank by 189 bps to 32.93% in 2026.
- The last three EBT Margin figures came in at 32.93% (Q1 2026), 37.16% (Q4 2025), and 36.66% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn | -32.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.93% |
| Dec 31, 2025 | 37.16% |
| Sep 30, 2025 | -36.66% |
| Jun 30, 2025 | -16.25% |
| Mar 31, 2025 | -63.89% |
| Dec 31, 2024 | -42.07% |
| Sep 30, 2024 | -60.25% |
| Jun 30, 2024 | -15.09% |
| Mar 31, 2024 | 42.29% |
| Dec 31, 2023 | -178.06% |
| Sep 30, 2023 | -125.20% |
| Jun 30, 2023 | -200.09% |
| Mar 31, 2023 | -258.92% |
| Dec 31, 2022 | -302.06% |
| Sep 30, 2022 | -293.87% |
| Jun 30, 2022 | -353.71% |
| Mar 31, 2022 | -302.88% |
| Dec 31, 2021 | -448.40% |
| Sep 30, 2021 | -481.64% |
| Jun 30, 2021 | -107.42% |